{"name":"Eye Therapies, LLC","slug":"eye-therapies-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Brimonidine Tartrate 0.025%","genericName":"Brimonidine Tartrate 0.025%","slug":"brimonidine-tartrate-0-025","indication":"Glaucoma or ocular hypertension (Phase 3 development)","status":"phase_3"}]}],"pipeline":[{"name":"Brimonidine Tartrate 0.025%","genericName":"Brimonidine Tartrate 0.025%","slug":"brimonidine-tartrate-0-025","phase":"phase_3","mechanism":"Brimonidine tartrate is an alpha-2 adrenergic agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.","indications":["Glaucoma or ocular hypertension (Phase 3 development)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQbkdZYTZNdTJFeDRKQ01OU2NYbUpqWlVYZGZfbGFoemk2eE1rZ0hMbHBBOWNuYmtRVVhpYzl2OHRXUzd4Q0xVZlNSTzc5VUhjbTJmcWpYclRvQmNBd0c1ZkZkRW5ROHlTQWtLc0NCdVZSTWtJeERVVEtmemFNdFliSzhHS3o4ZGZCWGhmVFI1NUlUcXMwRS1WbDROQVBGbnBRZzJwNjcxbzBvTGJ2dVBRZThFdWxyd1Izai1ZOTRUcGJ1ZVI5b21JX0xXd09QWV9ERXc?oc=5","date":"2026-02-11","type":"deal","source":"Quiver Quantitative","summary":"OKYO Pharma Limited Transitions ATM Equity Offering to Leerink Partners LLC for Enhanced Capital Access - Quiver Quantitative","headline":"OKYO Pharma Limited Transitions ATM Equity Offering to Leerink Partners LLC for Enhanced Capital Access","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPQVJiM3lQaVcyT0NPQy1fNVdYMWxxWnhha0x0c2FRbVZ0S2Z5RkxNRVBQZG85X2M1a3A4eWxYaVNsSGJlYWNZbmxtYU1kQVlBQ3BxamVxcC04XzlLWU4tVnFXX0xaaHVZYXZVdTRBb2JEcUtHbWstUEJQMVdBTm9kUXJEVFdlbzZSZEJLYWRZNGtYd2t2ajFZTkVXVXEtdzNzMWxBVnNEU0JjYUZZdlNRWTY4ajkySkhGZl9CdTlPMjhidw?oc=5","date":"2026-01-29","type":"trial","source":"Fierce Pharma","summary":"As Roche eyes busy 2026, Vabysmo undershoots targets and Tecentriq fails early lung cancer study - Fierce Pharma","headline":"As Roche eyes busy 2026, Vabysmo undershoots targets and Tecentriq fails early lung cancer study","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNTGdEZmlISFJEb25wRUFqUk44YjF0OGQ3aGstYzc2el9tbEFYZjV6SjJnUVZRTTNKdzlhRFhVRGdDT0d1eUtvVGlHaTZCVUJRVm5FYWJiYW4zSlRGUTMtVDY4aWw0ZlFoWmxaT29JazdBVERPa2IzVU50M1hVYndCZWd4cmYwdG5pSmFKMVFremhxQkl2bGxQNnh1MC0xakNa?oc=5","date":"2026-01-16","type":"regulatory","source":"Ophthalmology Advisor","summary":"FDA Alerts: Ophthalmology Drug and Device Approvals - Ophthalmology Advisor","headline":"FDA Alerts: Ophthalmology Drug and Device Approvals","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPNVYteHk1b2ZvNWx3QUdtbGNkYTdpc0xJZnVIUVMzRk1hSXhSMVFBRTNhX0dCU0Z5dlR6ZkpqSlc2eVVoaGlIOGM2Q2lxVVRvdUdvTEw3QkllQkRqWEVTbzJTTXMxOHpIbDh2NkdNWVM0NndHYjZBakdJWTA4TGVVeHdNby14S0JsdVlncHlOQTJtVjlWUTJNaXZUcEx6ZDRfenBFdEtQaldOb2c3UXRyRlppSG9oYWZ5N0c2ZGhWWVNFeXU2eDFsd1NJZUQ0RVlWSHJKMU1hdlVSVGloTXVDRndKdThwZWpO?oc=5","date":"2026-01-05","type":"pipeline","source":"globenewswire.com","summary":"OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer - globenewswire.com","headline":"OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOeVRIc3hVbmNpRG9aUUxiSV8tbDBUcjdzZHR6dnRBSGNkLUxuc21RcFloLTlzOUpZQ2RYbEdfZF9DQUNxSHZheExGQ2JRdzJ0ZmYtZG95SkxiUkFUMHFPUHdLQnR5R05sdHpRTmVZX2pzUFcyaC1MU0hXMldlMlEwRUFJVnd4RVM2RGdhREZSdDVCRUxzY1FB?oc=5","date":"2025-11-04","type":"trial","source":"The Business Journals","summary":"Columbus biopharma company secures $18M for diabetic dry eye treatment trials - The Business Journals","headline":"Columbus biopharma company secures $18M for diabetic dry eye treatment trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQVmh3MVNIODZLcFh4Q1YzUGRZc2tmam5CUnFUdVhiM0dhWFlpcW11N2JWMVhFQ3pZekJwODF0RkdkOGNCSjd6bUwwdGMtWkpoSS1ZZ3N3N0dkekhibFUwNFR3b3lORmlEZ3EzbktsZlJEWHN6UkFhWWh2cmNNdVhiR09iR2toVUY0Mm0yc2k3TEIyUTNwc1VLclZrWks4TzJMc0RaNnYyMEhuRXhkblhwakd4R1ExcEhEOXdocXFBdU1OZ0k?oc=5","date":"2025-11-03","type":"trial","source":"Fierce Biotech","summary":"Italian biotech AAVantgarde adds $141M series B to fund retinal disease gene therapy trials - Fierce Biotech","headline":"Italian biotech AAVantgarde adds $141M series B to fund retinal disease gene therapy trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPdmtSNzRBd0MyWmVSNTF2Y2pGNVZUVU5BMkFoSFA0QVdhTW9CNWx0eG5NYnhhZG5ZSWJ1enRlaW5oaWRZR0VoLURWaWN0dWdWemlFWTd5RGJ4emZjZGNtNU53NmhIdHhZaVNzMFJWUTI3NUxnMy1SdWppWkNLSUVTVElqbjFNTEZkLXJLa3k0djlBX3BWOXdCT1NudmJZb1NzOXVyeA?oc=5","date":"2025-10-08","type":"pipeline","source":"Ophthalmology Times","summary":"Ocular surface: Targeted therapies for a multifactorial problem - Ophthalmology Times","headline":"Ocular surface: Targeted therapies for a multifactorial problem","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQRmdaV2hHLUp6d1VQc3BfaVl3SU8zcmcwcm9DSlBGQmNTb2VwQ0JBNEFtbmFYSU1IS3Y3UENEWndRQ1J6M04zcUIyd1ZzeDg2TGJIbjI3enVEdDRncHhOb0hiMEplSFpZcXFkamdlVWFlTV9UcFdkc0FxdXYwbFRxT0NkSlJoSUR6UG1HQU03eDE5UXlKN0N6TNIBVkFVX3lxTE53VUxnWXRZV2kzTUdzT2ZOOFJfblZmdnRtUjdHYkhRSVl6SENBMUt6cl9aZExOLXZCWmpOMUJVMTZOa0VCdXRpckNodDljc0hEUGRsRV9n?oc=5","date":"2025-07-01","type":"patent","source":"Law360","summary":"Fed. Circ. Faults PTAB Ax Of Patent On Bausch Eye Drops - Law360","headline":"Fed. Circ. Faults PTAB Ax Of Patent On Bausch Eye Drops - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNRk13d3VjS1Y5OHlXSjV2R0Y5TGN0d3lkWExtSzU4bWpDVDhEZ1ZBcjBSeFVveEVkX0xSWEFlZFVkNWlOdGtBTml1b3pPYVp0NXBGRUM0dWh3YkdSNmY2ZEVwVnRKd0ZHMTVtV0kwNW1ZLTB3TnZHQjZWaC04d3lFWg?oc=5","date":"2025-06-30","type":"patent","source":"Patently-O","summary":"Eye Therapies v. Slayback: Federal Circuit Abandons Standard Transition Construction - Patently-O","headline":"Eye Therapies v. Slayback: Federal Circuit Abandons Standard Transition Construction - Patently","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNUTlueFcxMloxdHhmMklNRmVicU9oc1hZMkY1dElEeUNUeWJTdmV2YzJycktUNG1STmthZ1FOLXBweTM4WTZCZVF4TXc3VHVXS01rdUhfMXVUZmp4N3VBQUR5RkI2M2Q3b1pGaGNzeG5OZDF1YmdHWFZVQkkyMS1HTV9zMG96WEluMk12MU5XaEVWWHhhZXpmZ19Fd2pSelNuN0FoVXozMERsVHd0YnJVdlYyb1d1LTNJU1NQdWItM3hxZ3RlZ01mcw?oc=5","date":"2025-01-28","type":"pipeline","source":"PR Newswire","summary":"Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight - PR Newswire","headline":"Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxPVXRzMU9RZXlZRVczNjlMSGxad19JbWR3LWhmb3phTlg0Mm12bDFYSE9mTEVaaTZqVTRrM3AtUmQyRC1WX1Mxbm9wbmNLRklVM2xMWW5lUlc0M0NQdGZDNF83ajFaQW9SaHotZlFBM1V1d0NmOXROV0pld0o0d09qbDFRZGVMVUxwcnNoNVRvakhNTnlrVG1STE50WVFndXVWblVSTWI0V21pMGF6YXNfWVh4UThuZjNWRW5vWHctSFpHbzZGQUU2ajAyRWs5MFE?oc=5","date":"2024-09-13","type":"pipeline","source":"Eyes On Eyecare","summary":"Sonoma Pharmaceuticals and EMC Pharma to co-market expanded eye care product line - Eyes On Eyecare","headline":"Sonoma Pharmaceuticals and EMC Pharma to co-market expanded eye care product line","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE10NUpPdU43bUdZU1pnU0R5c0lWUzlEQ3BLd0dXTjM3YTFUa2pyMWZ1QklxeFBrTzBhcHJTVnBwN0xMWncybmk0WlhuQzR2NnlQajhOcXI1em01d1ZOSlptSmsxdF9Wc1hlNHd3OGxBWVdXNjNIeGFCd1ZDQklFbVU?oc=5","date":"2022-05-23","type":"deal","source":"Drug Delivery Business","summary":"Alcon to pay $60M to acquire Kala Pharmaceuticals’ dry eye treatment - Drug Delivery Business","headline":"Alcon to pay $60M to acquire Kala Pharmaceuticals’ dry eye treatment","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}